PRESS RELEASES

Date Title and Summary View
Toggle Summary Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018
NORCROSS, Ga. , April 18, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, has been selected as an expert speaker and will participate in
View HTML
Toggle Summary Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis
NORCROSS, Ga. , April 16, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today provided highlights from a late-breaker oral presentation at The International Liver Congress™  2018 , European Association for the
View HTML
Toggle Summary Galectin Therapeutics to Present Late-Breaker Oral Presentation at The International Liver Congress 2018
GR-MD-02 treatment in NASH cirrhosis patients without esophageal varices shows statistically significant and clinically meaningful effects NORCROSS, Ga. , April 04, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. ( NASDAQ:GALT ) , the leading developer of therapeutics that target galectin
View HTML
Toggle Summary Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
NORCROSS, Ga. , April 02, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.   (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at the H.C.
View HTML
Toggle Summary Galectin Therapeutics Reports 2017 Financial Results and Provides Business Update
NORCROSS, Ga. , March 29, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results for the year ended December 31, 2017 . These results are included in the Company's Annual Report on Form
View HTML
Toggle Summary Galectin Therapeutics to Present at Two International Conferences in March
NORCROSS, Ga. , March 09, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will participate in two upcoming international  conferences in
View HTML
Toggle Summary Galectin Therapeutics to Present at 2nd Annual H.C. Wainwright NASH Investor Conference
NORCROSS, Ga. , March 08, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Dr. Harold Shlevin , the Company’s Chief Operating Officer, will present at the 2 nd Annual H.C.
View HTML
Toggle Summary Galectin Therapeutics Announces Record Date and Annual Stockholders Meeting Date for 2018
NORCROSS, Ga. , March 05, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced March 26, 2018 is the record date for the 2018 Annual Meeting of Stockholders to be held on May 22, 2018 in Atlanta, GA.
View HTML
Toggle Summary Galectin Therapeutics to Present at 30th Annual ROTH Conference
NORCROSS, Ga. , Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at the 30th Annual ROTH Conference on March 12, 2018
View HTML
Toggle Summary Galectin Therapeutics to Present at BIO CEO & Investor Conference
NORCROSS, Ga. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc.  (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber , M.D., the Company’s CEO and CMO, will present at BIO CEO & Investor Conference on Tuesday,
View HTML